ERNA Insider Trading

Insider Ownership Percentage: 20.50%
Insider Buying (Last 12 Months): $2,030,995.68
Insider Selling (Last 12 Months): $0.00

Eterna Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Eterna Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eterna Therapeutics Share Price & Price History

Current Price: $4.65
Price Change: Price Increase of +0.1 (2.20%)
As of 02/2/2023 01:00 AM ET

This chart shows the closing price history over time for ERNA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Eterna Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/2/2022John D HalpernMajor ShareholderBuy335,920$3.28$1,101,817.60450,961View SEC Filing Icon  
12/2/2022Nicholas Jason SingerDirectorBuy283,286$3.28$929,178.08266,214View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Eterna Therapeutics (NASDAQ:ERNA)

Eterna Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/1/2023Cypress Point Wealth Management LLC94,375$0.30M0.5%N/A3.210%Search for SEC Filing on Google Icon
1/31/2023Naviter Wealth LLC79,621$0.39M0.1%N/A2.708%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Eterna Therapeutics logo
Eterna Therapeutics Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Brooklyn, New York.
Read More on Eterna Therapeutics

Today's Range

Now: $4.65
Low: $4.55
High: $4.87

50 Day Range

MA: $4.07
Low: $3.03
High: $5.49

52 Week Range

Now: $4.65
Low: $2.73
High: $51.40

Volume

8,144 shs

Average Volume

20,808 shs

Market Capitalization

$13.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.23

Who are the company insiders with the largest holdings of Eterna Therapeutics?

Eterna Therapeutics' top insider investors include:
  1. John D Halpern (Major Shareholder)
  2. Nicholas Jason Singer (Director)
Learn More about top insider investors at Eterna Therapeutics.

Who are the major institutional investors of Eterna Therapeutics?

Eterna Therapeutics' top institutional shareholders include:
  1. Cypress Point Wealth Management LLC — 3.21%
  2. Naviter Wealth LLC — 2.71%
  3. Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of Eterna Therapeutics stock.

Which major investors are buying Eterna Therapeutics stock?

Within the previous quarter, ERNA stock was acquired by institutional investors including:
  1. Cypress Point Wealth Management LLC
  2. Naviter Wealth LLC
During the previous year, these company insiders have bought Eterna Therapeutics stock:
  1. John D Halpern (Major Shareholder)
  2. Nicholas Jason Singer (Director)
Learn More investors buying Eterna Therapeutics stock.